Hope Rugo: Imlunestrant with or without abemaciclib vs SOC ET presented by Komal Jhaveri
Hope Rugo, Professor of medicine at the University of California San Francisco, shared a post on X:
“Imlunestrant with or without abemaciclib vs SOC ET presented/pub today by Komal Jhaveri. Imlunestrant improved PFS in ESR1m, and abemaciclib improved PFS post CDKi in all and with mPIK3CA. Best CDK post-CDK data to date and potential new SOC. No info on duration of prior CDK.”
More posts featuring Hope Rugo.
Read the post “Highlights from Day 1 of SABCS 2024” on oncodaily.com.
Dr. Hope Rugo, is a professor of medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. With experience in hematology and oncology, she specializes in breast cancer treatment and clinical trials.
Dr. Rugo’s research focuses on innovative therapies and combination treatments to improve outcomes for breast cancer patients, including immunotherapy and targeted agents. She is known for her contributions to reducing treatment toxicity educating through initiatives like the Breast Forum.
Dr. Komal Jhaveri holds the Patricia and James Cayne Chair for Junior Faculty and serves as an Associate Member in the Breast Medicine Service and Early Drug Development at Memorial Sloan Kettering Cancer Center.
As Section Head of the Endocrine Therapy Research Program and Clinical Director of the Early Drug Development Service, Dr. Jhaveri focuses on innovative approaches for breast cancer treatment, particularly in early-phase clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023